| 產(chǎn)品名稱 |
Kasumi-3 |
| 商品貨號(hào) |
B182324 |
| Organism |
Homo sapiens, human |
| Tissue |
peripheral blood |
| Cell Type |
lymphoblast |
| Product Format |
frozen |
| Morphology |
myeloblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
acute myeloblastic leukemia |
| Age |
57 years |
| Gender |
male |
| Ethnicity |
Japanese |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
t(3:7) (q27;q22), del(5)(q15), del(9)(q32), add(12)(p11) |
| Derivation |
The cell line was established from the blast cells of a myeloperoxidase-negative acute leukemia patient.
Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.
- |
| Clinical Data |
57 years
Japanese
male
|
| Comments |
The cell line expresses CD7, CD4, CD13, CD33, CD34, HLA-DR and c-Kit on cell surface compatible with that of acute myelocytic leukemia, subtype M0 (AML-M0).
Kasumi-3 has t(3;7)(q27:q22), del(5)(q15), del(9)(q32), and add(12)(p11) chromosomal abnormalities. The breakpoint of 3q27 is located near the EVI1 gene.
A high level of expression of the EVI1 gene was observed.
Kasumi-3 cells treated with TPA showed maturation to monocytic lineage.
Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing |
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 105 viable cells/mL.
Interval: Maintain cell density between 3 x 105 and 3 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile |
Amelogenin: X,Y CSF1PO: 11 D13S317: 11,12 D16S539: 9,11 D5S818: 12 D7S820: 10,11 THO1: 6,9 TPOX: 8 vWA: 16,18 |
| Population Doubling Time |
45 to 60 hrs |
| Name of Depositor |
H Asou |
| Deposited As |
human |
| Year of Origin |
July 18, 1990 |
| References |
Asou H, et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn. J. Cancer Res. 87: 269-274, 1996. PubMed: 8613429
Mochizuki N, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96: 3209-3214, 2000. PubMed: 11050005
Suzukawa K, et al. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics 42: 356-360, 1997. PubMed: 9192861
Suzukawa K, et al. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia 13: 1359-1366, 1999. PubMed: 10482986
|
